Clinical Study

Viela Bio A Randomized, Double-Blind, Multicenter,Placebo-Controlled Phase 3 Study With Open-Label Period To Evaluate The Efficacy And Safety Of Inebilizumab In Adults With Myasthenia Gravis

Posted Date: Mar 5, 2021

  • Investigator: Hani Kushlaf
  • Specialties:
  • Type of Study: Drug

Randomized, double-blind, placebo-controlled, parallel-group study with optional open-label extension


Adult Subjects Aged = 18 Years With Acetylcholine Receptor Antibody Positive (Achr-Ab+) Or Muscle-Specific Kinase-Antibody Positive (Musk-Ab+) Generalized Mg



For More Information:

Elizabeth Gehlmann

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.